![Quiver Logo](/static/img/logo-icon.png)
![ONVO logo](https://quiver-logos.s3.us-east-2.amazonaws.com/onvo.png)
Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ONVO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of ONVO by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ONVO's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to ONVO
Recent picks made for ONVO stock on CNBC
ETFs with the largest estimated holdings in ONVO
Flights by private jets registered to ONVO
![Quiver Logo](/static/img/logo-icon.png)